Burden of illness in idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a life-threatening condition, and few data concerning the impact on healthcare utilization and associated costs are available. The objective of this study was to describe the burden of illness (comorbidity, healthcare resource utilization, and associated costs) in patients with idiopathic pulmonary fibrosis. METHODS: Two cohorts (patients with idiopathic pulmonary fibrosis and matched controls) were retrospectively identified from US claims databases between January 1, 2001 and September 30, 2008. Cases with idiopathic pulmonary fibrosis were defined by age of 55 years or older and either two or more claims with a code for idiopathic fibrosing alveolitis (ICD-9 516.3), or one claim with ICD 516.3 and a subsequent claim with a code for post-inflammatory pulmonary fibrosis (ICD-9 515). The prevalence and incidence of pre-selected comorbidities, healthcare resource utilization (hospital, outpatient, drugs), and direct medical costs were assessed in each cohort. RESULTS: A total of 9286 patients with idiopathic pulmonary fibrosis were identified. When compared with age- and gender-matched controls, these patients were at significantly increased risk for comorbidities including pulmonary hypertension and emphysema. The all-cause hospital admission rate (0.5 per person-year) and the all-cause outpatient visit rate (28.0 per person-year) were both ∼2-fold higher than in controls. Total direct costs for patients with idiopathic pulmonary fibrosis were $26,378 per person-year; the incremental costs over controls were $12,124 (2008 value). CONCLUSIONS: Patients with idiopathic pulmonary fibrosis experience increased comorbidity, healthcare resource utilization, and direct medical costs compared to controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Gribbin, J., Hubbard, R., & Smith, C. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.001 · Cited by 132
Cited by
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Raghu, G., Amatto, V. C., Behr, J., & Stowasser, S. (2015) · European Respiratory Journal · doi:10.1183/13993003.02316-2014 · Cited by 463
Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis
Larson-Casey, J. L., Deshane, J. S., Ryan, A. J., Thannickal, V. J., & Carter, A. B. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.001 · Cited by 428
“Pulmonary fibrosis is a devastating disorder that has an increasing prevalence of over 60 per 100,000 persons, and the cost of care has had a dramatic upward trend in recent years (Collard et al., 2015; Collard et al., 2012).”
BackgroundIncidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old
Raghu, G., Chen, S.-Y., Hou, Q., Yeh, W.-S., & Collard, H. R. (2016) · European Respiratory Journal · doi:10.1183/13993003.01653-2015 · Cited by 338
Self-citationEpidemiology of idiopathic pulmonary fibrosis
Ley, B., & Collard, H. (2013) · Clinical Epidemiology · doi:10.2147/clep.s54815 · Cited by 321
“Collard et al assessed the overall burden of illness in IPF including comorbidities, health care resource utilization, and health care costs by searching two United States insurance claims databases between 2001 and 2008.(73) Cases of IPF required both age .”
Self-citationThe therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Lancaster, L., Crestani, B., Hernandez, P., Inoue, Y., Wachtlin, D., Loaiza, L., Quaresma, M., Stowasser, S., & Richeldi, L. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000397 · Cited by 209
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis
Ley, B., Swigris, J., Day, B.-M., Stauffer, J. L., Raimundo, K., Chou, W., & Collard, H. R. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0091oc · Cited by 206
Self-citationDempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202007-901oc · Cited by 101
Myeloid-derived suppressor cells are necessary for development of pulmonary hypertension
Bryant, A. J., Shenoy, V., Fu, C., Marek, G., Lorentsen, K. J., Herzog, E. L., Brantly, M. L., Avram, D., & Scott, E. W. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0214oc · Cited by 47
Metadata
- Authors
- Collard, H. R., Ward, A. J., Lanes, S., Cortney Hayflinger, D., Rosenberg, D. M., & Hunsche, E.
- Venue
- Journal of Medical Economics
- Publisher
- Informa Healthcare
- Published
- 2012-04-25
- Volume
- 15
- Issue
- 5
- Pages
- 829-835
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W2147335168
- Cited by
- 208
- References
- 3
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.